14 /100
LOW RISK
Score updated Jul 14, 2026

ELVN — Enliven Therapeutics, Inc. Dilution Risk Tracker

Track ELVN dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ELVN — Get alerts when the score changes →

As of July 14, 2026, Enliven Therapeutics, Inc. (ELVN) has a DilutionWatch DilutionScore of 14/100, rated LOW dilution risk. Enliven Therapeutics, Inc. has a market capitalization of $2.41B, 60.90M shares outstanding, 175 institutional holders tracked. Key dilution vectors include approximately 62 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
22
💰 Cash Runway
0
📊 Float Risk
30
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for ELVN.
🔔 Track ELVN — Get forecast alerts →

💹 Market Data

Market Cap$2.41B
Shares Outstanding60.90M
Float44.42M
Cash$452.40M
Debt$302.0K
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 6.3% shares (2026Q1 vs prior)
175 institutional holders · 67.12M shares
#1 ORBIMED ADVISORS LLC 7.96M shares
#2 FMR LLC 6.83M shares
#3 Polar Capital Holdings Plc 5.07M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest8.53M
Days to Cover3.1
% of Float19.2%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2023
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for ELVN Shareholders

Enliven Therapeutics, Inc. (ELVN) has a DilutionScore of 14/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 14, 2026.

DilutionWatch's EDGAR monitoring for ELVN shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for ELVN in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for ELVN alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track ELVN Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ELVN — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for ELVN
📊 ELVN FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 ELVN Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.